Abstract
Get full access to this article
View all access options for this article.
References
1.
Kammer
RB
. Moxalactam: Clinical summary of efficacy and safety . Rev Infect Dis
1982 ; 4 (suppl ): S712 –9 .
2.
Perlino
CA
. Moxalactam therapy for bacterial pneumonia . Rev Infect Dis
1982 ; 4 (suppl ): S617 –22 .
3.
Saito
A
. Clinical evaluation of moxalactam in the treatment of respiratory tract infections, hepatobiliary infections, and septicemia . Rev Infect Dis
1982 ; 4 (suppl ): S623 –8 .
4.
Salzer
W
Pegram
PS
Jr
McCall
CE
. Clinical evaluation of moxalactam: Evidence of decreased efficacy in gram-positive aerobic infections . Antimicrob Agents Chemother
1983 ; 23 : 565 –70 .
5.
Lentino
JR
Rytel
MW
Moore
E
. Therapy of lower respiratory tract infections with moxalactam . Antimicrob Agents Chemother
1981 ; 19 : 801 –6 .
6.
Winston
DJ
Busuttil
RW
Kurtz
TO
Young
LS
. Moxalactam therapy for bacterial infections . Arch Intern Med
1981 ; 141 : 1607 –12 .
7.
Cipolle
RJ
Seifert
RD
Zakse
DE
Strate
RG
. Hospital acquired gram-negative pneumonias: Response rate and dosage requirements with individualized tobramycin therapy . Therapeut Drug Monit
1980 ; 2 : 359 –63 .